No Data
GeneDx to Participate in Upcoming Investor Conference
GeneDx Holdings(WGS.US) Director Sells US$3.32 Million in Common Stock
GeneDx Holdings(WGS.US) 10% Shareholder Sells US$10.39 Million in Common Stock
GeneDx Holdings(WGS.US) Officer Sells US$3.2 Million in Common Stock
Form 144 | GeneDx Holdings(WGS.US) Officer Proposes to Sell 3.29 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 19, $GENEDX HOLDINGS CORP C/WTS 22/07/2026 (TO PUR COM)(WGSWW.US)$、$GeneDx Holdings(WGS.US)$ Officer Ryan Jason intends to sell 47,000 shares of its common stock on Nov 19,
GeneDx Fuels Rare Disease Drug Discovery With Launch of GeneDx Discover
Bigmoney Dreamer : ALWAYS KNOW YOUR RISK TOLERANCE
The risk level for GeneDx Holdings Corp. is high due to multiple factors that elevate volatility and potential drawdowns. The company's inability to maintain profitability and high debt levels relative to cash position are concerning for long-term financial stability. GeneDx's impressive short-term stock surge, while promising, rests heavily on recent positive news, making the price susceptible to sudden reversals if sentiments shift. Moreover, the stock's failure to establish clear support after the recent high suggests a fragile price structure, increasing the likelihood of a sharp downturn if market conditions worsen. The absence of sector-level support further heightens risk, positioning the stock as a highly speculative trade.